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OBJECTIVES The aim of the present study was to determine whether streptozotocin (STZ)-induced
hyperglycemia exacerbates progressive left ventricular (LV) dilation and dysfunction after
myocardial infarction (MI).
BACKGROUND Diabetes mellitus (DM) adversely affects the outcomes in patients with MI. However, it is
unknown whether DM can directly affect the development of post-MI LV remodeling and
failure.
METHODS Male mice were injected intraperitoneally with STZ (200 mg/kg; DM group) or vehicle only.
At two weeks, MI was created in the STZ-injected (DMMI group) or vehicle-injected
mice (MI group) by left coronary artery ligation, and they were followed up for another four
weeks.
RESULTS Survival during six weeks was significantly lower in the DMMI versus MI group (25% vs.
71%; p  0.01), despite a similar infarct size (60  2% vs. 61  2%; p  NS).
Echocardiography after two weeks of ligation showed LV dilation and dysfunction with MI,
both of which were exaggerated in the DMMI group. Likewise, LV end-diastolic pressure
and lung weight were increased in mice with MI, and this increase was enhanced in the
DMMI group. The myocyte cross-sectional area in the non-infarcted LV increased to a
similar degree in the DMMI and MI groups, whereas the collagen volume fraction was
greater in the DMMI group. Deoxyribonucleic acid laddering was greater in the DMMI
group.
CONCLUSIONS Hyperglycemia decreased survival and exaggerated LV remodeling and failure after MI by
increasing interstitial fibrosis and myocyte apoptosis. Diabetes mellitus could be a risk factor
for heart failure, independent of coronary artery lesions. (J Am Coll Cardiol 2003;42:
165–72) © 2003 by the American College of Cardiology Foundation
Diabetes mellitus (DM) is one of the greatest comorbid
factors in patients with acute myocardial infarction (MI).
Diabetic patients with MI have a higher incidence of death
than do non-diabetic patients, both in the short-term phase
and on long-term follow-up (1). The excess mortality of
diabetic patients results primarily from the development of
congestive heart failure (HF) and recurrent MI (2).
Myocardial infarction frequently produces progressive left
ventricular (LV) dilation associated with hypertrophy of the
non-infarcted LV. These changes in LV geometry, referred
to as remodeling, contribute to the development of de-
pressed cardiac function (3). Several mechanisms, whether
alone or in combination, may adversely affect LV remodel-
ing and failure after MI in patients with DM; such
mechanisms include severe coronary artery disease (CAD),
impaired vasodilatory reserve of coronary arteries, and pre-
existing LV dysfunction probably due to diabetic cardiomy-
opathy (4). Clinical studies in patients with acute MI have
shown that the mortality is higher in diabetic patients,
despite similar ejection fractions and similar coronary pa-
tency rates (5). These results raise the possibility that
diabetes may adversely affect the LV remodeling process and
lead to a higher incidence of HF among diabetic patients.
However, it has been difficult to evaluate the impact of
diabetes, per se, on post-MI remodeling in patients because
of concomitant CAD. To overcome these limitations in
clinical studies, we employed the animal model of HF due
to MI by coronary artery ligation.
Therefore, the purpose of this study was to determine
whether streptozotocin (STZ)-induced hyperglycemia ex-
acerbates progressive LV chamber dilation and contractile
dysfunction in a murine model of MI. Moreover, there is
increasing evidence that myocyte hypertrophy and apoptosis
in association with interstitial fibrosis are enhanced not only
in diabetic (6) but also in post-MI hearts (7). Thus, we
determined whether these remodeling processes may be mu-
tually reinforcing in the setting of MI associated with diabetes,
and DM may further enhance the development of HF.
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METHODS
Experimental design. The study was approved by our
institutional Animal Research Committee and conformed
to the Animal Care Guidelines of the American Physiolog-
ical Society. Four groups of mice were studied in the present
study. Diabetes mellitus was induced in male CD-1 mice (5
to 8 weeks old and 25 to 35 g body weight) by intraperito-
neal injection of STZ (200 mg/kg body weight) (8,9). Tail
vein blood glucose samples were measured five days after
injection to ensure induction of diabetes. As a control,
vehicle (0.1 mol/l citrate buffer, pH 4.5) was injected in
another group of mice. At two weeks after injection, MI was
created in STZ-injected (DMMI group) or vehicle-
injected mice (MI group) by ligating the left coronary artery
(10). A sham operation without ligating the coronary artery
was also performed in additional groups of STZ-injected
(DM group) and saline-injected mice (control group). All
four groups of mice (control, DM, MI, and DMMI) were
followed up for another two weeks (for two-week post-MI
study) and four weeks (for six-week survival study).
EXPERIMENT 1: SIX-WEEK SURVIVAL STUDY. The survival
analysis was performed in the control (n  8), DM (n  7),
MI (n  28), and DMMI (n  28) groups of mice.
During the study period of six weeks (two weeks after
vehicle or STZ injection and another four weeks after
surgery), cages were inspected daily for deceased animals.
All deceased mice were examined for the presence of pleural
effusion and cardiac rupture.
EXPERIMENT 2: TWO-WEEK POST-MI STUDY. The following
studies were performed in a separate experiment using
groups of mice after four weeks (two weeks after vehicle or
STZ injection and another two weeks after surgery).
Echocardiographic and hemodynamic measurements.
Echocardiographic studies were performed under light an-
esthesia with tribromoethanol/amylene hydrate (Avertin;
2.5% wt/vol, 8 l/g intraperitoneally) and spontaneous
respiration. A two-dimensional parasternal short-axis view
of the LV was obtained at the level of the papillary muscles.
In general, the best views were obtained with the transducer
lightly applied to the mid to upper left anterior chest wall.
The transducer was then gently moved cephalad or caudad
and angulated until desirable images were obtained. After it
was ensured that the imaging was on axis (based on the
roundness of the LV cavity), two-dimensional targeted
M-mode tracings were recorded at a paper speed of 50
mm/s. Under the same anesthesia with Avertin, a 1.4F
micromanometer-tipped catheter (Millar Instruments,
Houston, Texas) was inserted into the right carotid artery
and then advanced into the LV to measure LV pressures
(10). One subset of investigators (S.H. and N.S.), who were
not informed of the experimental groups, performed in vivo
LV function studies.
In our recent validation study (11), we reported excellent
reliability of LV cavity dimension and fractional shortening
measurements, in which an echocardiographic method sim-
ilar to that used in this study was employed. The intraob-
server and interobserver variabilities between two measure-
ments divided by the mean value of the two measurements,
expressed as a percentage, were 10%. The measurements
made in the same animals on separate days were also highly
reproducible. Therefore, our technique could be considered
to allow noninvasive assessment of LV structure, even in
mice with large MIs.
Tissue preparation and morphometric analysis. The
heart was excised and dissected into the right and left
ventricles, including the septum. The LV was cut into three
transverse sections: apex, middle ring, and base. From the
middle ring, 5-m sections were cut and stained with
Masson’s trichrome. The boundary lengths of the infarcted
and non-infarcted endocardial and epicardial surfaces were
traced with a planimeter digital image analyzer. Infarct size
(fraction of the infarcted LV) was calculated as the average
of all slices and expressed as the percentage of circumference
length (10). Myocyte cross-sectional area was determined by
quantitative morphometry of tissue sections from the
mid-LV (10). To measure collagen volume fraction, we
stained collagens in paraffin-embedded tissue sections
(5-m thick) with sirius red (12). Briefly, the sections were
rinsed with distilled water and treated with 0.1% picrosirius
red solution in saturated, aqueous picric acid for 60 min.
The sections were further washed in 0.01 mol/l HCl for 2
min, dehydrated, and mounted. Collagen fibers could be
identified through polarization microscopy.
Apoptosis Assay. The myocardial tissues with MI were
carefully dissected into three parts: the infarcted LV; the
border-zone LV with the peri-infarct rim (1-mm rim of
normal-appearing tissue); and the remaining non-infarcted
(remote) LV. We examined whether apoptosis is present in
the non-infarcted LV by the more sensitive ligation-
mediated polymerase chain reaction (LM-PCR) fragmen-
tation assays (ApoAlert LM-PCR ladder assay kit; Clone-
tech, Palo Alto, California) (13).
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
CAD  coronary artery disease
DM  diabetes mellitus
DMTU  dimethylthiourea
dP/dt  rate of rise in left ventricular pressure
HF  heart failure
LV  left ventricle/ventricular
MCP  monocyte chemoattractant protein
MI  myocardial infarction
ROS  reactive oxygen species
STZ  streptozotocin
TGF  transforming growth factor
TNF  tumor necrosis factor
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LV angiotensin-converting enzyme (ACE) activity, oxi-
dative stress, and cytokine/chemokine gene expression.
The following studies were performed using the non-
infarcted LVs obtained from a separate group of additional
control, DM, MI, and DMMI mice treated identically, as
described earlier.
Left ventricular ACE activity was measured by the rate of
generation of His-Leu from a hippuryl-His-Leu substrate
and expressed as nmol/mg tissue/h. The amount of reactive
oxygen species (ROS) was quantified in LV tissues by
electron spin resonance spectroscopy with 4-hydroxy-
2,2,6,6-tetramethyl-piperidine-N-oxyl (hydroxy-TEMPO)
(14). All measurements were performed in two parallel runs,
in the presence and absence of the hydroxyradical scavenger,
dimethylthiourea (DMTU). The expression level of genes,
including transforming growth factor (TGF)-beta, tumor
necrosis factor (TNF)-alpha, and monocyte chemoattrac-
tant protein (MCP)-1 was determined by a ribonuclease
protection assay (15). The value of each hybridized probe
was normalized to that of glyceraldehyde-3-phosphate-
dehydrogenase in each template set as an internal control.
Plasma biochemical measurement. Before sacrifice, ve-
nous blood samples (1 ml) were collected for determination
of plasma glucose, blood urea nitrogen (BUN), and aspar-
tate aminotransferase (AST).
Statistical analysis. Data are expressed as mean  SEM.
Survival function estimates during the follow-up period
were derived using the Kaplan-Meier method, and differ-
ences between groups were assessed by the log-rank test.
Comparison of means between groups was performed by
one-way analysis of variance, followed by post hoc t tests.
The Bonferroni correction was done for multiple compari-
sons of means in the three groups of DM, MI, and
DMMI with that of the control group and between the
MI and DMMI groups. p  0.05 was considered statis-
tically significant.
RESULTS
Survival and blood chemistry. The mortality rates during
6 h after ligation were 3% and 7% in MI and DMMI
mice, respectively (p  NS). Survival rates during the study
period were significantly lower in DMMI versus MI mice
(25% vs. 71%, p 0.01) (Fig. 1). Death was suspected to be
attributable to HF and/or arrhythmia. One DMMI
mouse (1%) and two MI mice (6%) died of LV rupture (p
 NS).
Plasma glucose levels were elevated in both DM and
DMMI mice after STZ injection, compared with control
mice (Table 1). Plasma BUN and AST, used to assess
potential renal and hepatic toxicity, respectively, were not
increased in the DM or DMMI group (Table 1).
Infarct size. Infarct size, determined by histomorphomet-
ric analysis of LV sections at two weeks after MI, was
comparable (60  2% vs. 61  2%; p  NS) between MI
(n  9) and DMMI mice (n  8). It was also comparable
(65  2% vs. 59  4%; p  NS) at three days after ligation,
at which time the LV cavity size was similar between MI (n
 6) and DMMI mice (n  8).
Echocardiography and hemodynamics. Echocardio-
graphy at two weeks after surgery demonstrated that DM,
per se, did not significantly affect LV diameter or shorten-
ing. In comparison with control mice, MI mice showed LV
dilation and dysfunction, both of which were significantly
exacerbated in the DMMI group (Fig. 2 and Table 2).
Heart rate was comparable among all groups (Table 2).
Mean aortic blood pressure was lower in the MI and
DMMI groups than in the control group, but there was
no significant difference between these two groups. Left
ventricular end-diastolic pressure was increased in the MI
group and further enhanced in the DMMI group. The
maximum rate of rise in LV pressure (dP/dtmax) was
decreased in the MI and DMMI groups. Minimum
dP/dt, an index of LV diastolic relaxation, was also lower in
the MI group. This decrease tended to be exaggerated in the
presence of DM, which, however, did not reach statistical
significance (p  0.09).
Organ weights. Body weight was lower in diabetic mice
(Table 2), as previously observed (6,8). In contrast, the tibial
length was similar among all groups. Coinciding with
Figure 1. Kaplan-Meier survival analysis. Percentages of surviving diabetes
mellitus (DM)myocardial infarction (MI) (n  28) and MI (n  28)
mice were plotted. Overall survival was significantly lower in DMMI
compared with MI mice. *p  0.01 compared with the MI group.
Table 1. Blood Chemistry at Four Weeks After Streptozotocin









Glucose (mg/dl) 117  6 473  16* 124  8 416  23*
BUN (mg/dl) 22.6  1.5 27.9  2.9 25.4  1.2 29.6  3.5
AST (IU/l) 35.2  9.6 48.5  8.4 34.4  4.5 45.5  8.3
*p  0.01 vs. control. Data are means  SEM.
AST  aspartate aminotransferase; BUN  blood urea nitrogen; DM  diabetes
mellitus; MI  myocardial infarction.
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increased LV end diastolic pressure, lung weight/tibial
length was increased in the MI group, which was also
exacerbated in the DMMI group. The prevalence of
pleural effusion was significantly higher in DMMI than
MI mice.
Histomorphometry. The myocyte cross-sectional area was
significantly increased in DM, MI, and DMMI mice
compared with control mice (Figs. 3A and 3B). However,
there was no significant difference in this parameter between
MI and DMMI mice. The collagen volume fraction was
Figure 2. M-mode echocardiograms obtained from a control (A), diabetes mellitus (DM) (B), myocardial infarction (MI) (C), and DMMI mouse (D)
two weeks after surgery. EDD  end-diastolic diameter (arrows). ECG  electrocardiogram.
Table 2. Echocardiographic, Hemodynamic Data, and Organ Weights of Mice
Control DM MI DMMI
Echocardiographic data
n 30 33 32 29
LVEDD (mm) 3.81  0.03 3.72  0.06 5.05  0.05† 5.30  0.06†§
LVESD (mm) 2.43  0.04 2.40  0.07 4.31  0.05† 4.70  0.07†§
Fractional shortening (%) 36.2  0.6 35.5  0.9 14.6  0.4† 11.6  0.4†§
Hemodynamic data
n 29 29 27 27
Heart rate (beats/min) 460  7 447  6 452  8 458  12
Mean AoP (mm Hg) 79  2 79  2 68  2† 69  3*
LV EDP (mm Hg) 3.0  0.5 4.8  0.5 17.7  1.3† 21.7  1.5†‡
dP/dtmax (mm Hg/s) 6,790  228 6,519  269 3,902  208† 3,485  221†
dP/dtmin (mm Hg/s) 5,063  150 4,425  148† 2,962  129† 2,485  137†
Organ weights
n 22 25 23 22
Body weight (g) 33.9  0.7 29.0  0.9† 30.9  0.6* 26.0  0.7†§
TL (mm) 21.1  0.1 20.9  0.1 21.1  0.1 20.8  0.1
LV weight/TL (mg/mm) 5.00  0.12 3.91  0.20† 4.86  0.15 4.51  0.15
RV weight/TL (mg/mm) 1.33  0.04 1.14  0.05 1.65  0.09* 1.75  0.10†
Lung weight/TL (mg/mm) 9.1  0.1 8.2  0.2 15.6  1.0† 18.5  1.2†‡
Pleural effusion (%) 0 0 28 53‡
*p  0.05, †p  0.01 vs. control. ‡p  0.05, §p  0.01 vs. MI. Data are means  SEM.
AoP aortic pressure; dP/dt rate of rise in left ventricular pressure; EDD end-diastolic diameter; EDP end-diastolic
pressure; ESD  end-systolic diameter; LV  left ventricular; RV  right ventricular; TL  tibial length; other abbreviations
as in Table 1.
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also increased in MI and DMMI mice, and this increase
was significantly greater in DMMI than MI mice (Figs.
3C and 3D).
Apoptosis. The intensity of the DNA ladder indicated that
the apoptosis in the non-infarcted LV from DMMI mice
was further increased compared with that of MI mice (Fig. 4).
Cytokines, ACE, and ROS. Left ventricular ACE activity
was significantly higher in the MI and DMMI groups
than in the control group (Table 3). However, it was
comparable between the MI and DMMI groups. The
amount of ROS in the LV, expressed as the “DMTU-
inhibitable” rate of electron spin resonance signal decay
(14), was significantly greater in MI than control
animals (Table 3). However, the extent of this increase
was similar in DMMI mice. Left ventricular gene ex-
pression of TGF-beta1 was increased in MI mice and
significantly exaggerated in DMMI mice (Fig. 5). In
addition, TNF-alpha and MCP-1 messenger ribonucleic
acid levels were increased in MI mice and enhanced in
DMMI mice.
Figure 3. (A) Representative light microscopic photomicrographs of Masson’s trichrome-stained myocardial sections obtained from control (a), diabetes
mellitus (DM) (b), myocardial infarction (MI) (c), and DMMI (d) mice. Scale bar represents 10 m. (B) Summarized data for myocyte cross-sectional area
from control (n  8), DM (n  8), MI (n  9), and DMMI (n  8) mice. (C) Representative light microscopic photomicrographs of sirius red-stained
myocardial sections obtained from MI (a) and DMMI (b) mice. Scale bar represents 10 m. (D) Summarized data for collagen volume fraction from control
(n  6), DM (n  6), MI (n  6), and DMMI (n  6) mice. Values are means  SEM. **p  0.01 compared with the control value; ††p  0.01 compared
with the corresponding MI value.
Figure 4. This deoxyribonucleic acid ladder indicative of apoptosis was
detectable in the genomic deoxyribonucleic acid from the left ventricle.
Apoptosis was further increased in the non-infarcted left ventricle of
diabetes mellitus (DM)myocardial infarction (MI) compared with MI
mice. Amplification of the engrailed-2 (En-2) gene was performed as an
internal control. bp  base pair; M  marker.
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DISCUSSION
The major novel finding of this study was that MI mice had
poor survival in the presence of DM. Diabetes mellitus
decreased overall LV ejection performance, exacerbated LV
remodeling, and increased chamber dilation as well as
myocyte apoptosis and interstitial fibrosis of the non-
infarcted myocardium. Therefore, this is the first report to
provide evidence that hyperglycemia can exacerbate
post-MI cardiac failure, even in the absence of CAD and
hypertension.
Clinical relevance. In the present study, DM was associ-
ated with LV diastolic dysfunction characterized by de-
creased dP/dtmin. In contrast, normal systolic function was
preserved in diabetic animals. Previous studies, despite some
discrepancies, have demonstrated that, in general, DM
presented with an early reduction in LV diastolic function,
followed by progressive LV systolic failure (16,17). Further-
more, as previously demonstrated (18), DM alone increased
myocyte size and interstitial fibrosis. However, the heart
rate as well as LV size and systolic function were not altered
in DM in the present study, which contrasts with some
previous studies in rats (17,19). These differences might be
due to differences in the species examined (mice vs. rats), the
methods used to evaluate contractile function (in vivo vs. ex
vivo), and the duration and severity of diabetes at which LV
function was determined. Myocardial infarction produced
LV cavity dilation associated with myocyte hypertrophy and
interstitial fibrosis of non-infarcted LV. These changes,
though significant, were modest compared with those seen
in four-week post-MI animals (11).
A number of clinical studies have reported that the
prognosis after MI is worse in diabetic patients who exhibit
a higher incidence of HF and death than in non-diabetics
(4). This may be due to the concomitant presence of severe
coronary atherosclerotic lesions in diabetic patients. How-
ever, both experimental and clinical studies have shown that
DM causes a specific form of myocardial damage indepen-
dent of coronary atherosclerosis and manifests itself as LV
dysfunction (20). In fact, STZ-induced diabetes has been
shown to result in greater contractile dysfunction after
ischemia and reperfusion (21). Therefore, a more likely
explanation for the increased occurrence of HF in diabetic
patients with MI is the exacerbation of LV remodeling due
to DM. However, no previous studies have examined the
impact of DM, per se, on post-MI remodeling and failure.
Thus, the present study clearly demonstrates, using an
animal model of MI caused by left coronary artery ligation,
that hyperglycemia can exacerbate post-MI LV failure.
Interestingly, despite a modest decline only in diastolic
function from DM alone, diabetic mice developed severe
systolic dysfunction after MI (Fig. 2 and Table 2).
Exacerbation of post-MI remodeling by DM. The dele-
terious effects of DM on myocardial function were not due
to infarct expansion, because the infarct size was not altered
at either three or 28 days after MI. It might be due to
progressive LV dilation caused by remodeling of the remote
region after healing of the infarct area. This LV remodeling
process is caused by a number of mechanisms. The present
results demonstrate that there was a significant increase in
the collagen volume fraction—namely, interstitial fibro-
sis—in the non-infarcted LV of DMMI compared with
MI mice (Fig. 3). Another intriguing finding is the increase
Table 3. Left Ventricular Angiotensin-Converting Enzyme Activity and Amount of Reactive Oxygen Species in Mice
Control DM MI DMMI
ACE activity (nmol/mg per h) 21.5  1.8 (n  4) 12.7  1.8 (n  4) 56.0  4.0* (n  4) 51.6  9.6* (n  3)
ROS amount (/min) 0.012  0.004 (n  7) 0.017  0.003 (n  7) 0.021  0.003† (n  6) 0.021  0.002† (n  6)
*p  0.01, †p  0.05 vs. control. Data are means  SEM.
ACE  angiotensin-converting enzyme; ROS  reactive oxygen species; other abbreviations as in Table 1.
Figure 5. Densitometric analysis of transforming growth factor (TGF)-beta1, tumor necrosis factor (TNF)-alpha, and monocyte chemoattractant protein
(MCP)-1 gene expression in control (n  8), diabetes mellitus (DM) (n  9), myocardial infarction (MI) (n  8), and DMMI (n  9) mice. Data were
normalized by GAPDH concurrently run on the same gel and expressed as the ratio to control values. Values are means  SEM. *p  0.05, **p  0.01
compared with the control value; ††p  0.01 compared with the corresponding MI value.
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of myocyte apoptosis in both the border and remote LV
after MI (Fig. 4). This is consistent with previous studies
showing the loss of myocytes as a result of apoptosis within
the non-infarcted LV (22,23). Although the pathophysio-
logic significance of myocyte apoptosis in post-MI remod-
eling and failure remains mostly speculative (24), progres-
sive loss of myocytes may lead to further deterioration of
cardiac structure and function (25). Furthermore, the ob-
served increase of interstitial fibrosis in DMMI animals
may also reflect an increase of cardiac myocyte death, which
leads to more replacement fibrosis. Taken together, these
observations suggest that exaggerated myocyte apoptosis
and interstitial fibrosis may play an important role in the
worsening of LV remodeling and failure in the presence of
diabetes (26).
Next, we examined the stimulating factors responsible for
enhanced interstitial fibrosis and apoptosis in the DMMI
mice. Recent studies have shown that the renin-angiotensin
system is activated in diabetes (27). Therefore, diabetes and
MI together may synergistically activate the renin-
angiotensin system in the heart, which may further damage
its function and structure. Another potential factor is
oxidative stress, which has also been shown to be enhanced
by hyperglycemia (28). Reactive oxygen species might be
involved in the induction of TNF-alpha gene expression
because hyperglycemia can produce ROS, which, in turn,
have been shown to trigger TNF-alpha gene expression
(29). However, there was no significant difference in the
extent of increase in myocardial ROS measured by electron
spin resonance techniques between MI and DMMI mice
(Table 3). Therefore, increased ROS production might not
play a major role in the exacerbation of LV remodeling and
failure in DMMI mice. In addition, myocardial ACE
activity was comparable between MI and DMMI mice.
The present study demonstrates that TGF-beta gene ex-
pression was increased in MI animals, which was signifi-
cantly exaggerated in the DMMI group (Fig. 5). Previous
studies have shown that diabetes is associated with increased
expression of TGF-beta (30). In addition, TGF-beta plays
an important role in myocardial fibrosis. Therefore, one
proposed mechanism by which DM exacerbates LV remod-
eling and failure is related to a further increase in TGF-beta
after MI and the resultant enhancement of cardiac fibrosis.
Interestingly, hyperglycemia significantly enhanced the gene
expression of TNF-alpha and MCP-1 in post-MI hearts.
The former (TNF-alpha) plays an important role in the
pathogenesis of myocardial remodeling and failure (15). In
addition, MCP-1 has been shown to be increased in failing
hearts (31). Although the functional role of MCP-1 and its
significance in myocardial failure remain unanswered, the
upregulation of MCP-1 by DM could promote the further
progression of HF. However, the present study does not
provide direct proof of a cause-and-effect relationship be-
tween the increase of cytokine/chemokine expression and
the exacerbation of LV failure by hyperglycemia. Further
investigation is clearly needed.
Study limitations. There are several potential limitations
to be acknowledged in this study. First, the amount of STZ
used in the present study was based on previous reports in
mice, in which 200 mg/kg body weight of STZ was used to
induce hyperglycemia (8,9). These doses of STZ are higher
than those used for rats (50 to 85 mg/kg) (17,19). This
might probably be due to the different sensitivity to STZ
between mice and rats. Plasma glucose levels in our animals
were increased up to 400 to 500 mg/dl (Table 1). Although
these values are similar to those reported by others in
diabetic mice (500 to 600 mg/dl) (8,9) and in rats (500
mg/dl) (16–18), they are greater than those in rats after the
injection of STZ 50 mg/kg body weight (267 mg/dl) (19).
Therefore, the relatively higher plasma glucose levels in our
animal model might contribute to the very poor outcome in
the DMMI mice and influence the clinical relevance of
this study. Second, the decrease in insulin sensitivity is
another important factor in DM and thus might play an
important role in the exacerbation of post-MI remodeling
and failure in the presence of DM. However, this crucial
point was not examined in the present study.
Clinical implications. The present results may well explain
the clinical observations that diabetes, per se, has a direct
adverse impact on the outcomes of patients after MI (4). In
addition to an acceleration of coronary atherosclerosis and
an impairment of collateral formation, diabetes-induced
exacerbation of LV remodeling and failure after MI is an
important pathogenic mechanism responsible for this phe-
nomenon. The findings in the present study may further
draw attention to the early and intensive treatment of HF in
diabetic patients with MI.
Conclusions. Streptozotocin-induced DM, independent
of CAD, exacerbated LV remodeling and failure after MI.
Myocyte apoptosis and interstitial fibrosis in post-MI hearts
were increased in the presence of hyperglycemia, which
might play an important role in the development of HF.
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